Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05174312 · ClinicalTrials.gov registry record · NA

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

A NA study of Acute Decompensated Heart Failure, sponsored by Reprieve Cardiovascular.

Completed
Registry status
NA
Development phase
100
Enrollment target
16
Study locations

NCT05174312 is a NA study of Acute Decompensated Heart Failure that has completed, run by Reprieve Cardiovascular. The registered enrollment target is 100 participants, below the 451-participant average among 12 other Acute Decompensated Heart Failure trials with a reported enrollment target (78% lower). The trial reports 16 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05174312, a NA study of Acute Decompensated Heart Failure, has completed, sponsored by Reprieve Cardiovascular.

COMPLETED
Registry status
NA
Development phase
100 participants
Enrollment target
16
Study locations

Study Summary

The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS can more efficiently decongest ADHF patients in comparison to Control Therapy.

Conditions Studied

Acute Decompensated Heart Failure

Interventions

  • DEVICE Reprieve Decongestion Management System
  • DRUG Diuretic

Study Locations (16)

North Carolina

  • Duke University Hospital - Durham
  • Cone Health - Greensboro
  • Atrium Health Wake Forest Baptist Medical Center - Winston-Salem

Missouri

  • St. Louis VA - St Louis
  • Washington University - St Louis

Ohio

  • The Lindner Research Center at Christ Hospital - Cincinnati
  • Ohio State University Hospital - Columbus

South Carolina

  • Medical University of South Carolina - Charleston
  • Prisma Health - Columbia

Texas

  • Ascension Texas Cardiovascular - Austin
  • Baylor Scott & White - Dallas

Alabama

  • Eastern Shore Research Institute - Fairhope

California

  • University of California Irvine - Irvine

District of Columbia

  • MedStar Washington Hospital Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2022-07-11
Est. Completion 2025-01-10
Phase NA

Sponsor

Reprieve Cardiovascular

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05174312

The ClinicalTrials.gov registry entry for NCT05174312 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 451-participant average among 12 other Acute Decompensated Heart Failure trials with a reported enrollment target (78% lower). The listed sponsor is Reprieve Cardiovascular, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Decompensated Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Reprieve Decongestion Management System is the first listed.

NCT05174312 reports 16 study locations spanning 10 distinct geographic areas - top geographies include North Carolina, Missouri, Ohio.

Frequently Asked Questions

What is clinical trial NCT05174312 about?

NCT05174312 is a clinical study titled "Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)". The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS can more...

What is the current status of trial NCT05174312?

This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2022-07-11. Estimated completion is 2025-01-10.

What conditions does trial NCT05174312 study?

This clinical trial studies the following conditions: Acute Decompensated Heart Failure.

What interventions are being tested in trial NCT05174312?

The interventions under investigation include: Reprieve Decongestion Management System (DEVICE), Diuretic (DRUG).

Who is sponsoring clinical trial NCT05174312?

This trial is sponsored by Reprieve Cardiovascular, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05174312 being conducted?

This trial has 16 study locations across Alabama, California, District of Columbia, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Decompensated Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Decompensated Heart Failure

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.